Tavist and Mitral valve incompetence - a phase IV clinical study of FDA data

Summary:

Mitral valve incompetence is reported as a side effect among people who take Tavist (clemastine fumarate), especially for people who are female, 40-49 old, also take Reglan, and have Atrial fibrillation/flutter.

The phase IV clinical study analyzes which people have Mitral valve incompetence when taking Tavist. It is created by eHealthMe based on reports of 2,141 people who have side effects when taking Tavist from the FDA, and is updated regularly.

What is Tavist?

Tavist has active ingredients of clemastine fumarate. eHealthMe is studying from 2,149 Tavist users. Check the latest studies of Tavist.

What is Mitral valve incompetence?

Mitral valve incompetence (inefficient heart valve) is found to be associated with 1,431 drugs and 1,280 conditions by eHealthMe. Check the latest studies of Mitral valve incompetence.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

2,141 people reported to have side effects when taking Tavist.
Among them, 11 people (0.51%) have Mitral valve incompetence.

Could Tavist cause Mitral valve incompetence?

Among these 11 people:

What is the gender of people who have Mitral valve incompetence when taking Tavist? *

female: 90.91 %
male: 9.09 %

What is the age of people who have Mitral valve incompetence when taking Tavist? *

What are other drugs people take besides Tavist? *

What are other side effects people have besides Mitral valve incompetence? *

Chest Pain: 6 people, 54.55%
Weight Increased: 5 people, 45.45%
Sinus Bradycardia (an unusually slow heartbeat due to heart disease): 5 people, 45.45%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 45.45%
Hypoaesthesia (reduced sense of touch or sensation): 5 people, 45.45%
Abdominal Distension: 5 people, 45.45%
Muscle Spasms (muscle contraction): 4 people, 36.36%
Sweating Increased (excess sweating): 4 people, 36.36%
Menometrorrhagia (a condition in which prolonged or excessive uterine bleeding occurs irregularly and more frequently than normal): 4 people, 36.36%
Pulmonary Congestion (congestion in the lungs): 4 people, 36.36%

What are the existing conditions these people have? *

Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Tavist and have Mitral valve incompetence?

- Check whether Mitral valve incompetence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tavist:

Tavist (2,149 reports)

Browse all side effects of Tavist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mitral valve incompetence:

Mitral valve incompetence (1,431 drugs)

Browse all the conditions that are associated with Mitral valve incompetence:

Mitral valve incompetence (1,280 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on clemastine fumarate (the active ingredients of Tavist) and Tavist (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.